EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Xiaolun Huang, Jiao Huang, Xinjing Li, Lin Chen

Clinical Pharmacology in Drug Development · 2023

DOI: 10.1002/cpdd.1219 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Xiaolun Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy of Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glyburide, Metformin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rational combination of oral antidiabetic agents is more likely to provide better glycemic control than monotherapy. Metformin glibenclamide tablets can be used as second‐line therapy for patients with type 2 diabetes mellitus who cannot successfully control their blood glucose levels by diet and exercise plus metformin or sulfonylureas. The aim of this study was to evaluate the bioequivalence and safety of metformin hydrochloride and glibenclamide tablets (500 mg/5 mg) prepared by 2 different vendors in healthy Chinese subjects under fasting and fed conditions. This is an open‐label, single‐center, randomized, 2‐formulation, 2‐period crossover study. After screening, 40 subjects were enrolled in the fasting trial, while 40 subjects were enrolled in the fed trial. Qualified subjects were randomly assigned to receive a monotherapy dose of 500 mg/5 mg of the test or reference formulation, and after a 1‐week washout period, they took the alternative formulation. Blood samples were collected from 24 blood collection sites per cycle for pharmacokinetic analysis until 36 hours after oral administration. In total, 78 subjects completed the study. Under fasting and fed conditions, the geometric mean ratios of maximum plasma concentration, area under the plasma concentration–time curve (AUC) from time 0 to time of last quantifiable drug level , and AUC from time 0 to infinity between the 2 products, as well as the corresponding 90%CIs, were all within the range of 80%–125%. It was found that exposure (AUC from time 0 to infinity) to metformin is decreased by about 25% in the fed state compared to fasting, whereas glibenclamide exposure is increased by about 30% in the fed state. No severe adverse events were observed in the study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GlyburideMetforminHumansCross-Over StudiesEast Asian PeopleFastingTabletsTherapeutic Equivalency

Stichwörter der Autor:innen

bioequivalencefasting and fedglibenclamidemetforminpharmacokinetics

Substanzen

GlucovanceGlyburideMetforminTablets

Autor:innen und Institutionen

  • College of Pharmacy of Jinan University, Guangzhou, China.
  • The First Affiliated Hospital of Jinan University, Guangzhou, China.

Zitieren

APA

Huang, X., Huang, J., Li, X., & Chen, L. (2023). Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1219

Vancouver

Huang X, Huang J, Li X, Chen L. Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1219

BibTeX
@article{Huang2023,
  author = {Huang, Xiaolun and Huang, Jiao and Li, Xinjing and Chen, Lin},
  title = {Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  doi = {10.1002/cpdd.1219}
}
Kostenlos starten →